OBSV - オブスイヴァ (ObsEva SA)

OBSVのニュース

   ObsEva down 42% on late-stage linzagolix data (NASDAQ:OBSV)  2020/07/06 15:29:21 Seeking Alpha
ObsEva SA (OBSV -41.8%) slumps on more than a 7x surge in volume on the heels of results from two Phase 3 clinical trials evaluating lead candidate linzago
   Livongo Health and Trevena among healthcare gainers; ObsEva among losers  2020/07/06 15:03:36 Seeking Alpha
Gainers: Trinity Biotech (NASDAQ:TRIB) +13%. Zynex (NASDAQ:ZYXI) +13%. Livongo Health (NASDAQ:LVGO) +12%. Trevena (NASDAQ:TRVN) +11%. Mesoblast MESO +11%.
   The Week Ahead In Biotech: Endo, Eagle Pharma FDA Decisions, ObsEva Late-Stage Readouts In Focus  2020/07/06 12:08:57 Benzinga
Biotech stocks rebounded in the holiday-shortened week ending July 2 as investors reacted to pending clinical trial readouts and the news flow surrounding COVID-19 vaccine and treatment development. Australian biopharma Alterity Therapeutics Ltd (NASDAQ: ATHE ) was among the biggest gainers of the week after the company said it received FDA guidance for the Phase 2 study for its Parkinsonian disorder drug. Inovio Pharmaceuticals Inc (NASDAQ: INO ) and Pfizer Inc. (NYSE: PFE )/ BioNTech SE – ADR (NASDAQ: BNTX ) were among the companies that issued updates on their coronavirus vaccine programs. The week also saw FDA issuing guidance on the approval of COVID-19 vaccines, with the agency suggesting a vaccine needs to demonstrate at least 50% efficacy in a placebo-controlled trial. The following are key catalysts for the unfolding … Full story available on Benzinga.com
   ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids  2020/07/06 05:00:00 GlobeNewswire
PRIMROSE 1 achieved statistically significant and clinically meaningful results across primary and key secondary endpoints at week 24 PRIMROSE 2…
   ObsEva SA to present at ESHRE Virtual 36th Annual Meeting, July 5-8, 2020  2020/07/03 05:00:00 GlobeNewswire
Geneva, Switzerland and Boston, MA – July 3, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing…
   ObsEva down 42% on late-stage linzagolix data (NASDAQ:OBSV)  2020/07/06 15:29:21 Seeking Alpha
ObsEva SA (OBSV -41.8%) slumps on more than a 7x surge in volume on the heels of results from two Phase 3 clinical trials evaluating lead candidate linzago
   Livongo Health and Trevena among healthcare gainers; ObsEva among losers  2020/07/06 15:03:36 Seeking Alpha
Gainers: Trinity Biotech (NASDAQ:TRIB) +13%. Zynex (NASDAQ:ZYXI) +13%. Livongo Health (NASDAQ:LVGO) +12%. Trevena (NASDAQ:TRVN) +11%. Mesoblast MESO +11%.
   The Week Ahead In Biotech: Endo, Eagle Pharma FDA Decisions, ObsEva Late-Stage Readouts In Focus  2020/07/06 12:08:57 Benzinga
Biotech stocks rebounded in the holiday-shortened week ending July 2 as investors reacted to pending clinical trial readouts and the news flow surrounding COVID-19 vaccine and treatment development. Australian biopharma Alterity Therapeutics Ltd (NASDAQ: ATHE ) was among the biggest gainers of the week after the company said it received FDA guidance for the Phase 2 study for its Parkinsonian disorder drug. Inovio Pharmaceuticals Inc (NASDAQ: INO ) and Pfizer Inc. (NYSE: PFE )/ BioNTech SE – ADR (NASDAQ: BNTX ) were among the companies that issued updates on their coronavirus vaccine programs. The week also saw FDA issuing guidance on the approval of COVID-19 vaccines, with the agency suggesting a vaccine needs to demonstrate at least 50% efficacy in a placebo-controlled trial. The following are key catalysts for the unfolding … Full story available on Benzinga.com
   ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids  2020/07/06 05:00:00 GlobeNewswire
PRIMROSE 1 achieved statistically significant and clinically meaningful results across primary and key secondary endpoints at week 24 PRIMROSE 2…
   ObsEva SA to present at ESHRE Virtual 36th Annual Meeting, July 5-8, 2020  2020/07/03 05:00:00 GlobeNewswire
Geneva, Switzerland and Boston, MA – July 3, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing…
   How ObsEva (OBSV) Stock Stands Out in a Strong Industry  2020/04/23 12:45:00 Zacks Investment Research
ObsEva (OBSV) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.
   ObsEva and Selecta Bio up premarket on bullish ratings  2020/01/29 12:04:04 Seeking Alpha
ObsEva (NASDAQ:OBSV) initiated with Buy rating and $19 (395% upside) price target at Kempen & Co. Shares up 8% premarket. Selecta Biosciences (NASDAQ:SELB)
   ObsEva's Menstrual Bleeding Drug Produces 'Best-In-Class' Response In Late-Stage Study  2019/12/09 16:53:16 Benzinga Feeds
Swiss biopharma Obseva SA (NASDAQ: OBSV ), which is developing orally administered, clinical-stage compounds to treat women's reproductive health conditions, announced a positive late-stage clinical readout Monday for its investigational compound to treat heavy menstrual bleeding due to uterine fibroids. ObsEva saw its shares a decline steeply in early November due to a failed trial of nolasiban, another pipeline asset. ObsEva's Study Results The Phase 3 study dubbed PRIMROSE 2 met the primary and secondary efficacy endpoints, ObsEva said. The study evaluated once-daily oral linzagolix in 100mg and 200mg doses, with and without hormonal add-back therapy, or ABT, The primary efficacy endpoint was the reduction in heavy menstrual bleeding. The responder rate was 93.9% for women receiving 200mg linzagolix with ABT and 56.7% for women receiving 100mg without ABT versus 29.4% for the placebo group. The company termed the response for the 200mg dose as "best-in-class." Both doses achieved significant rates of amenorrhea, reduction …
   ObsEva Enters Oversold Territory  2019/11/15 15:47:00 Zacks Investment Research
ObsEva SA has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
   The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval  2019/11/15 12:08:29 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) China Biologic Products Holdings Inc (NASDAQ: CBPO )(reacted to its third-quarter results) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Halozyme Therapeutics, Inc. (NASDAQ: HALO )(priced its debt offering) IGM Biosciences Inc (NASDAQ: IGMS ) Kodiak Sciences Inc (NASDAQ: KOD ) Novo Nordisk A/S (NYSE: NVO ) Seattle Genetics, Inc. (NASDAQ: SGEN ) XOMA Corp (NASDAQ: XOMA ) XBiotech Inc (NASDAQ: XBIT ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 14) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Altimmune Inc (NASDAQ: ALT ) (reacted to its third-quarter results) Auris Medical Holding Ltd (NASDAQ: EARS ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) (priced its common stock offering) Cellectar Biosciences Inc (NASDAQ: CLRB ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc.

calendar